Canopy Growth’s (NYSE:CGC,TSX:WEED) board has dismissed Bruce Linton, co-founder and co-CEO of the Canadian cannabis producer, as its leading executive.

On Wednesday (July 3) the Canadian cannabis producer confirmed Linton would be departing the company effective immediately.


Fellow Canopy Growth co-CEO Mark Zekulin will become the sole CEO for the firm. However, he will participate in the search for new leadership.

In an interview with Squawk Box, Linton confirmed he did not step down from the firm but instead was terminated.

The now departing executive said once Canopy Growth closed on the second investment injection worth C$5 billion from Constellation Brands (NYSE:STZ) last August, a condition was set for the board to be reconfigured. The New York-based alcohol company currently holds a 38 percent stake in Canopy Growth.

“I think the board had decided they wanted a different chair and a different co-CEO,” Linton said during a televised interview. “So I’m out effective immediately and there’s a search to replace the transitioning co-CEO.”

Despite termination, Linton shows support for Canopy Growth

Under Linton’s tenure, Canopy grew from the first publicly traded marijuana company in Canada to obtain a New York Stock Exchange listing and having a current market valuation of C$18.45 billion.

In a statement, Linton said that, while his turn at the company was over, he was confident in the team replacing him.

“I personally remain committed to a successful transition over the coming year as we begin a process to identify new leadership that will drive our collective vision forward,” Zekulin said in a statement.

Canopy Growth’s biggest investor disappointed with results

Following its blockbuster investment deal into Canopy Growth in November 2017, beverage maker Constellation Brands gained its stake and allowed the marijuana firm to head out and seek a variety of acquisitions with the cash injections it received.

During a quarterly earnings call in June with analysts and investors, Bill Newlands, CEO of Constellation Brands, said his firm was disappointed in the recent quarterly results from Canopy Growth.

As part of its own quarterly results, Constellation Brands indicated that losses tied to the stake in Canopy Growth reached US$106 million on a reported basis, according to a report from the Canadian Press.

“While we remain happy with our investment in the cannabis space and its long-term potential, we were not pleased with Canopy’s recent reported year-end results,” Newlands said.

“However, we continue to aggressively support Canopy on a more focused, long-term strategy to win markets and form factors that matter while paving a clear path to profitability.”

Canopy posted a significant increase in revenues thanks to legalization, but its expansion plans did not help for the bottom line results.

The Canadian producer reported a net loss for Q4 2019 of C$323.3 million for the quarter, resulting in a net loss per share of C$0.98. Over the whole fiscal year, the company posted a net loss of C$685.4 million, indicating a net loss per share of C$2.57.

Canopy also reported an earnings before interest, tax, depreciation and amortization (EBITDA) loss of C$257 million in fiscal 2019, attributed to the investments of the company. The EBITDA loss for the company in fiscal 2018 was C$36.1 million.

Despite an early drop, shares of Canopy Growth quickly saw a marginal rise in Toronto on Wednesday. As of 1:37 p.m. EDT, the firm’s stock was up 1.73 percent to a price of C$53.40.

In New York, the company closed the half trading day—due to the Fourth of July holiday—with a 2.45 percent boost for a price of US$41.06 per share.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less